Company / Return on Equity (ROE)
ArriVent BioPharma, Inc. Return on Equity (ROE) History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-31.2%
FY2024
5-year range
-31.2% / -31.2%
FY2024-FY2024
Trend
-
vs FY2023
Sector context
#101 of 190
Health Care
What the data says
At -31.2%, ArriVent BioPharma, Inc.'s return on equity (roe) ranks #101 of 190 in the Health Care sector.
Based on SEC 10-K filings.
-31.2% in FY2024.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#101 of 190 in Health CareTop 53% of 190This company -31.2% Sector average -50.3%
▼
+37.9% above sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -31.2% | - |
| FY2023 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026